Raymond James Financial Inc. Acquires New Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Raymond James Financial Inc. acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 10,099 shares of the company's stock, valued at approximately $190,000.

A number of other institutional investors also recently modified their holdings of PCRX. PNC Financial Services Group Inc. raised its holdings in Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after buying an additional 513 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock valued at $184,000 after purchasing an additional 918 shares during the last quarter. Caitlin John LLC lifted its position in shares of Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after purchasing an additional 1,776 shares in the last quarter. Teacher Retirement System of Texas lifted its position in shares of Pacira BioSciences by 17.4% during the fourth quarter. Teacher Retirement System of Texas now owns 13,708 shares of the company's stock valued at $258,000 after purchasing an additional 2,034 shares in the last quarter. Finally, Global Alpha Capital Management Ltd. lifted its position in shares of Pacira BioSciences by 5.7% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 39,900 shares of the company's stock valued at $752,000 after purchasing an additional 2,160 shares in the last quarter. 99.73% of the stock is owned by institutional investors.

Pacira BioSciences Trading Up 1.0%

Shares of PCRX traded up $0.26 during trading hours on Friday, reaching $25.86. 1,145,487 shares of the company traded hands, compared to its average volume of 971,239. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -12.74 and a beta of 0.56. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $31.64. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock's fifty day moving average price is $24.88 and its 200 day moving average price is $22.44.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. HC Wainwright raised their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research report on Tuesday, April 8th. Barclays raised their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and lifted their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, Needham & Company LLC reduced their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Pacira BioSciences has a consensus rating of "Hold" and an average price target of $26.44.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.